JP Morgan analyst Andrea Teixeira maintains Procter & Gamble (NYSE:PG) with a Neutral and lowers the price target from $152 to $140.
Windtree Therapeutics Announces Publication From Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT) is a biotechnology company focused on advancing late-stage interventions for acute cardiovascular disorders of acute heart
